Please assess the completion status of the following clinical trial:

Trial Title: Taxol(Paclitaxel),UFT and Leucovorin in Patients With Advanced Gastric Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. At least 18 years old~2. Patients with histologically confirmed gastric adenocarcinoma, defined as locally advanced unresectable or metastatic or recurrent disease~3. Patients with at least one measurable lesion~4. ECOG performance status of 0,1 or 2~5. Patients with no prior chemotherapy and radiotherapy for metastatic disease (patients who have received and completed prior adjuvant chemotherapy at least 6 months prior to study enrollment may be enrolled into the study, prior taxane chemotherapy should be excluded)~6. Patients with physiological functions (bone marrow, heart, liver, kidney, etc.) meeting the following criteria: WBC \>4000/mm3, ANC \>1500/mm3, PLT \>100,000/mm3, Hb \>9.0g/dL, ALT\<3 times the ULN (\<5 times the ULN for liver metastasis cases), Total bilirubin \<1.5mg/dL, Creatinine \<the upper limit of normal~7. Accessible for treatment and follow-up~8. Give written informed consent~9. Women of child bearing potential must have a negative plasma or urine pregnancy test within 72 hours prior to start of the study medication~Exclusion Criteria:~1. Patients who received surgery within 14 days prior to enrollment~2. Patients with CNS metastasis~3. History of hypersensitivity related to the administration of polyoxyethylated-castor-oil (cremophor EL)-containing preparation (e.g. cyclosporin,etc.) or hardened-castor-oil-containing preparation (e.g. vitamin preparation for injection,etc.)~4. Patients with a history of severe hypersensitivity~5. Active infectious symptoms~6. Patients with active gastrointestinal bleeding, intestinal obstruction or other situation that dose not allow oral intake of medication~7. Patients with ascites that adversely affects performance status~8. Pre-existing CTC Grade 2 or greater neuropathy (motor or sensory)~9. Pregnant or nursing females~10. Patients who have participated in other clinical trials within 30 days prior to the first dose of the study drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).